$700M BNB Move Fails to Save Windtree From Nasdaq Delisting

Windtree Therapeutics, a biotech agency that lately introduced a $700 million BNB treasury technique, has been delisted from Nasdaq for failing to fulfill a list requirement. The BNB Impressed Rally and Subsequent Plunge Biotech firm Windtree Therapeutics, which introduced a large $700 million BNB treasury transfer, has had its inventory delisted from Nasdaq for failing […]



Source link